News | April 07, 2025
Dr Reddy’s Laboratories gets Rs 2,395 crore show cause notice from IT authority
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Subscribe To Our Newsletter & Stay Updated
